Top Markets
#1 CyberDEX CyberDEX +391.95%
#2 OVERTAKE OVERTAKE +58.99%
#3 Clearpool Clearpool +25.94%
#4 Playnance Playnance +23.93%
#5 deBridge deBridge +22.97%
#6 B3 (Base) B3 (Base) +20.83%
#7 Nillion Nillion +19.56%
#8 AUKI AUKI +19.09%
#9 Codatta Codatta +17.25%
#10 龙虾 (Lobster) 龙虾 (Lobster) +17.03%
Coin of the day
CyberDEX CyberDEX
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Kedudukan dalam Saham #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Harga Saham
$0.00185055
Modal Pasaran
$48.29K
Perubahan (1 hari)
-3.55%
Perubahan (1 tahun)
30.31%
Negara
GB
Perdagangan Nuformix plc (NFX)

Kategori

Healthcare
Pendapatan untuk Nuformix plc (NFX)
Pendapatan pada Mar 2026 TTM: $-857.89K
Menurut laporan kewangan terkini Nuformix plc, pendapatan semasa syarikat ialah $-857.89K. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $-4.88M, penurunan berbanding pendapatan pada tahun 2023 yang berjumlah $-754.56K. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Nuformix plc dari 2014 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-857.89K -3.39%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -614,967.33%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 359,735.34%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 468,046.88%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -227,477.01%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH